Reconstituting a BPC-157 TB-500 blend for muscle repair follows a standard peptide protocol: mix the lyophilized powder with bacteriostatic water, then store it properly. For a typical 5 mg BPC-157 and 5 mg TB-500 blend vial, add 2 mL of bacteriostatic water to achieve a concentration of 2.5 mg/mL for each peptide. A common dosage for muscle repair is 250 mcg of each peptide injected subcutaneously once daily, which equals 0.1 mL on an insulin syringe. This guide explains each step in detail, including dosage calculations, injection technique, and cycle length, with a focus on availability in Canada.
What is the BPC-157 TB-500 blend?
BPC-157 and TB-500 are research peptides often combined to accelerate muscle repair. BPC-157, a pentadecapeptide derived from gastric juice, promotes angiogenesis and tendon healing. TB-500, a synthetic fragment of thymosin beta-4, enhances cell migration and reduces inflammation. Together, they create a synergistic effect that supports recovery from muscle strains, tears, and other soft tissue injuries. Researchers in Canada frequently source this blend from specialized peptide suppliers.
How to reconstitute the BPC-157 TB-500 blend
Reconstitution is the process of dissolving the freeze-dried peptide powder into a liquid for injection. Follow these steps carefully to maintain peptide stability.
Materials needed
- BPC-157 TB-500 blend vial (typically 5 mg/5 mg)
- Bacteriostatic water (sterile water with 0.9% benzyl alcohol)
- Insulin syringe (1 mL with 29-31 gauge needle)
- Alcohol swabs
Step-by-step reconstitution
- Wipe the rubber stopper of the peptide vial and the bacteriostatic water vial with an alcohol swab.
- Draw 2 mL of bacteriostatic water into the insulin syringe. Insert the needle into the peptide vial at an angle and slowly inject the water against the glass wall to avoid foaming.
- Gently swirl the vial until the powder dissolves completely. Do not shake, as this can damage the peptides.
- Once clear, the solution is ready. Each mL now contains 2.5 mg of BPC-157 and 2.5 mg of TB-500.
For a deeper look at BPC-157 reconstitution specifically for muscle injuries, see the BPC-157 dosage protocol for muscle injuries in Quebec.
BPC-157 TB-500 blend dosage for muscle repair
The standard dosage for muscle repair is 250 mcg of each peptide once daily. This dose is drawn as 0.1 mL from the reconstituted solution. Some protocols use twice-daily dosing for severe injuries, but once daily is sufficient for most cases. The cycle typically lasts 4 to 6 weeks, followed by a break to prevent desensitization.
Dosage calculation table
Using the 2 mL reconstitution volume, here is a quick reference:
- 250 mcg dose = 0.1 mL (10 units on an insulin syringe)
- 500 mcg dose = 0.2 mL (20 units)
- 1 mg dose = 0.4 mL (40 units)
Always verify your calculations. A common error is confusing units with milliliters; remember that 1 mL equals 100 units on a standard insulin syringe.
Injection technique and sites
Inject the blend subcutaneously into fatty tissue. The abdomen, thigh, or upper arm are suitable sites. Rotate injection sites to avoid lipoatrophy. Pinch the skin, insert the needle at a 45-degree angle, and inject slowly. Do not inject directly into the injured muscle, as systemic absorption is effective for healing.
Storage after reconstitution
Store the reconstituted peptide in the refrigerator at 2-8°C. It remains stable for up to 30 days. Avoid freezing and keep away from light. If you notice cloudiness or particles, discard the vial. For long-term storage, keep the lyophilized powder in the freezer until reconstitution.
Cycle length and expected results
A typical BPC-157 TB-500 cycle for muscle repair runs 4 to 6 weeks. Some researchers extend to 8 weeks for chronic injuries. Results vary, but many report reduced pain and improved mobility within 2 to 3 weeks. The peptides work by promoting new blood vessel formation and collagen synthesis, which gradually strengthens the damaged tissue. For a comparison of these peptides, read BPC-157 vs TB-500 for recovery in Quebec.
Side effects and safety considerations
BPC-157 and TB-500 are generally well-tolerated in research settings. Reported side effects include mild injection site reactions, fatigue, or headaches. These usually resolve quickly. No severe adverse effects are documented at standard doses, but long-term human data is limited. Always use sterile techniques to prevent infection.
Where to buy BPC-157 TB-500 blend in Canada
Canadian researchers can purchase this blend from online peptide vendors that ship domestically. Look for suppliers offering third-party purity testing and lyophilized products. Prices range from CAD 60 to CAD 120 per 5 mg/5 mg vial. Ensure the vendor complies with Canadian regulations for research chemicals. For a detailed weekly dosage calculator, check TB-500 weekly dosage calculator and protocol.
Frequently asked questions
Can I mix BPC-157 and TB-500 in the same syringe?
Yes, they are commonly combined in one injection. The blend vial simplifies this, but if using separate vials, draw both into the same syringe after reconstitution. Ensure compatibility by using bacteriostatic water for both.
How long does the blend take to work?
Acute injuries may show improvement in 1-2 weeks, while chronic muscle damage might take 4-6 weeks. Consistency with daily injections is key.
Do I need to cycle off?
Yes, cycling prevents receptor downregulation. After a 4-6 week cycle, take at least 2 weeks off before restarting.
Is a prescription needed in Canada?
These peptides are sold for research purposes only and are not approved by Health Canada for human use. They do not require a prescription when purchased as research chemicals.
Summary of the protocol
To use the BPC-157 TB-500 blend for muscle repair in Canada: reconstitute with 2 mL of bacteriostatic water, inject 250 mcg (0.1 mL) subcutaneously once daily for 4-6 weeks, and store in the refrigerator. This protocol supports tissue healing through angiogenesis and anti-inflammatory pathways. Always source from reputable Canadian vendors and follow sterile procedures.
Self-administration of unapproved compounds carries risks that are not fully characterised in the published literature.